Brain Cancer Vaccine: 90 Percent Survival

December 18, 2013  10:59

Agenus Inc said more than 90 percent of patients treated with its experimental brain cancer vaccine were alive six months after undergoing surgery to remove the tumors, Newsmav Health reports.

Agenus shares soared as much as 32 percent in early trading.

The individualized protein-based vaccine is derived from a patient's own tumors, after 90 percent or more of the tumors have been surgically removed.

Each vaccine is designed to activate a patient's immune system to specifically target and destroy cancer cells.

Follow NEWS.am Medicine on Facebook and Twitter


 
  • Read also
 
  • Event calendar
 
 
  • Archive